Columbia University Study Suggests Benefits of Zyflamend(R) in the Early Treatment of Prostate Cancer

The data, published in the October edition of Nutrition andCancer, showed Zyflamend(R), a patented formulation from New Chapter,has the ability, in vitro, to reduce prostate cancer cellproliferation by as much as 78 percent and to induce cancer cell deathor apoptosis.

The research confirms Zyflamend(R) has COX-1 and COX-2anti-inflammatory effects, although its anti-cancer affects againstprostate cancer were independent of COX-2 inhibition, supporting thepostulation that some prostate cancer cells are not affected by COX-2inflammation.

"These results were particularly surprising and show great promisein the fight against prostate cancer," said researcher Dr. Debra L.Bemis of the Columbia University Department of Urology. "We hope thatthe magnitude of benefits shown in this research will be confirmed inthe larger scale trial already in progress."

Based on this research, Zyflamend(R) shows value in early therapyfor prostate cancer patients. COX inhibitors have also shown value forprostate cancer patients, but data from recent trials of selectiveCOX-2 inhibitors such as sulindac (Clinoril(R)) and celecoxib(Celebrex(R)), suggest that use of these drugs might have adversecardiovascular effects. The more widely utilized general COXinhibitor, aspirin, is not associated with these negative side effectsand, instead, has well-established beneficial effects for individualswith cardiovascular disease. Zyflamend(R) has a biochemical actionprofile that resembles aspirin more than these selective COX-2inhibitors.

Dr. Bemis added: "Zyflamend(R) is derived from natural herbalsources and is readily available in health food and nutritionalsupplement stores. Given the impressive data we're reporting,Zyflamend is a potentially more convenient and desirable means totarget the enormous population that is susceptible to prostatecancer."

On the strength of this laboratory research, Columbia University'sDepartment of Urology has commenced a Phase 1 human clinical trialtesting Zyflamend's ability to prevent prostate cancer in patientswith prostatic intraepithelial neoplasia (PIN).

PIN is a clinical precursor for prostate cancer. Withoutintervention, men diagnosed with PIN have a 50 to 70 percentlikelihood of developing prostate cancer. Although there are toolsthat detect the early signs of prostate cancer, such as PIN orelevated prostate specific antigen (PSA) levels, there is no consensusas to the optimal therapy for these patients.

"We are very encouraged about the early results of this phase 1trial," said Aaron E. Katz, M.D., associate professor of urology atColumbia University College of Physicians and Surgeons, Director ofthe Center of Holistic Urology at Columbia University Medical Centerand principal investigator of the study.

"We are encouraged that this study provides additional scientificevidence that specific herbal preparations can produce a positiveimpact on prostate health," said Mark Blumenthal, founder andexecutive director of the non-profit American Botanical Council. "Withso many people using herbal supplements for their health, new researchdocumenting their safety and benefits is encouraged and welcomed."

About New Chapter, Inc.: New Chapter is a widely respectedproducer, formulator, packager and distributor of organic probioticnutrients and herbal formulations selling over 90 products toapproximately 3000 retail locations. Its three main categories includeProbiotic Nutrients, Supercritical Therapy and MycoMedicinals. BearGrowth Capital Partners recently provided equity capital to supportthe company's anticipated growth plans. More information about NewChapter can be found at http://www.newchapter.info

The Herbal Supplement

Zyflamend is a patented formulation from New Chapter, Inc. ofBrattleboro, VT. It includes proprietary extracts of rosemary,turmeric, ginger, holy basil, green tea, hu zhang, Chinese goldthread,barberry, oregano, and Baikal skullcap.

Columbia University Medical Center provides internationalleadership in pre-clinical and clinical research, in medical andhealth sciences education, and in patient care. The medical centertrains future leaders in health care and includes the dedicated workof many physicians, scientists, nurses, dentists, and public healthprofessionals at the College of Physicians & Surgeons, the School ofDental & Oral Surgery, the School of Nursing, the Mailman School ofPublic Health, the biomedical departments of the Graduate School ofArts and Sciences, and allied research centers and institutions.Columbia University Medical Center researchers are leading thediscovery of novel therapies and advances to address a wide range ofhealth conditions. www.cumc.columbia.edu

About Bear Growth Capital Partners: Bear Growth Capital Partners("BGCP") is an affiliate of BSMB, the private equity arm of BearStearns & Co. (NYSE:BSC). BGCP focuses on making investments in middlemarket companies valued between $10 and $100 million. BGCP will investin compelling growth capital opportunities, traditional buyouts,recapitalizations, co-investments, and control and minority ownershippositions alongside superior management teams and other private equitysponsors. More information about BGCP can be found athttp://www.bsmb.com.